The FDA approved Pfizer and Astellas Pharma’s Xtandi, or enzalutamide, as a treatment for men with non-metastatic castration- -More- …
Astellas
With FDA nod, Pfizer and Astellas’ Xtandi gets its shot at blockbuster sales boost
Pfizer and Astellas have their chance to bring Xtandi to prostate cancer patients before their disease has spread. But it’ll be a mano a mano with Johnson & Johnson, whose rival drug Erleada…
FDA priority review status granted to Astellas’ AML drug
Astellas Pharma’s gilteritinib, which is being developed as a treatment for adult patients with relapsed/refractory FLT3-posi -More- …
Priority review for Astellas’ AML drug
Astellas Pharma’s gilteritinib is under priority review in the US as potential treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.